ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0490

Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality
Abstract Number: 0491

Small Molecule Metabolites, Potential Disease-specific Biomarkers for Predicting Treatment Response in Rheumatoid Arthritis
Abstract Number: 0492

A Machine Learning Model for the Early Identification of Rheumatoid Arthritis: Development and Validation
Abstract Number: 0493

An Algorithm Pipeline for Automated Metrical Analysis of Joint Swelling in Rheumatoid Arthritis via Smartphone Hand Photographs
Abstract Number: 0494

Usefulness of the Neutrophil-to-Lymphocyte Ratio, the Platelet-to-Lymphocyte Ratio and the Systemic Immune Inflammatory Index in Assessing Disease Activity in Rheumatoid Arthritis Patients
Abstract Number: 0495

Correlation Between Triglyceride/Glucose Index and Functional Capacity in Rheumatoid Arthritis Patients
Abstract Number: 0496

Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints
Abstract Number: 0497

Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis
Abstract Number: 0498

ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 0499

PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment
Abstract Number: 0500

An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years
Abstract Number: 0501

How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)
Abstract Number: 0502

Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study
Abstract Number: 0503

Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations
Abstract Number: 0504

Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].